Cargando…
Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)
Cancer immunotherapy based on the use of antibodies targeting the so-called checkpoint inhibitors, such as programmed cell death-1 receptor, its ligand, or CTLA-4, has shown durable clinical benefit and survival improvement in melanoma and other tumors. However, there are some special situations tha...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009216/ https://www.ncbi.nlm.nih.gov/pubmed/33782108 http://dx.doi.org/10.1136/jitc-2020-001664 |
_version_ | 1783672837040504832 |
---|---|
author | Gonzalez-Cao, Maria Puertolas, Teresa Riveiro, Mar Muñoz-Couselo, Eva Ortiz, Carolina Paredes, Roger Podzamczer, Daniel Manzano, Jose Luis Molto, Jose Revollo, Boris Carrera, Cristina Mateu, Lourdes Fancelli, Sara Espinosa, Enrique Clotet, Bonaventura Martinez-Picado, Javier Cerezuela, Pablo Soria, Ainara Marquez-Rodas, Ivan Mandala, Mario Berrocal, Alfonso |
author_facet | Gonzalez-Cao, Maria Puertolas, Teresa Riveiro, Mar Muñoz-Couselo, Eva Ortiz, Carolina Paredes, Roger Podzamczer, Daniel Manzano, Jose Luis Molto, Jose Revollo, Boris Carrera, Cristina Mateu, Lourdes Fancelli, Sara Espinosa, Enrique Clotet, Bonaventura Martinez-Picado, Javier Cerezuela, Pablo Soria, Ainara Marquez-Rodas, Ivan Mandala, Mario Berrocal, Alfonso |
author_sort | Gonzalez-Cao, Maria |
collection | PubMed |
description | Cancer immunotherapy based on the use of antibodies targeting the so-called checkpoint inhibitors, such as programmed cell death-1 receptor, its ligand, or CTLA-4, has shown durable clinical benefit and survival improvement in melanoma and other tumors. However, there are some special situations that could be a challenge for clinical management. Persons with chronic infections, such as HIV-1 or viral hepatitis, latent tuberculosis, or a history of solid organ transplantation, could be candidates for cancer immunotherapy, but their management requires a multidisciplinary approach. The Spanish Melanoma Group (GEM) panel in collaboration with experts in virology and immunology from different centers in Spain reviewed the literature and developed evidence-based guidelines for cancer immunotherapy management in patients with chronic infections and immunosuppression. These are the first clinical guidelines for cancer immunotherapy treatment in special challenging populations. Cancer immunotherapy in chronically infected or immunosuppressed patients is feasible but needs a multidisciplinary approach in order to decrease the risk of complications related to the coexistent comorbidities. |
format | Online Article Text |
id | pubmed-8009216 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-80092162021-04-16 Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM) Gonzalez-Cao, Maria Puertolas, Teresa Riveiro, Mar Muñoz-Couselo, Eva Ortiz, Carolina Paredes, Roger Podzamczer, Daniel Manzano, Jose Luis Molto, Jose Revollo, Boris Carrera, Cristina Mateu, Lourdes Fancelli, Sara Espinosa, Enrique Clotet, Bonaventura Martinez-Picado, Javier Cerezuela, Pablo Soria, Ainara Marquez-Rodas, Ivan Mandala, Mario Berrocal, Alfonso J Immunother Cancer Position Article and Guidelines Cancer immunotherapy based on the use of antibodies targeting the so-called checkpoint inhibitors, such as programmed cell death-1 receptor, its ligand, or CTLA-4, has shown durable clinical benefit and survival improvement in melanoma and other tumors. However, there are some special situations that could be a challenge for clinical management. Persons with chronic infections, such as HIV-1 or viral hepatitis, latent tuberculosis, or a history of solid organ transplantation, could be candidates for cancer immunotherapy, but their management requires a multidisciplinary approach. The Spanish Melanoma Group (GEM) panel in collaboration with experts in virology and immunology from different centers in Spain reviewed the literature and developed evidence-based guidelines for cancer immunotherapy management in patients with chronic infections and immunosuppression. These are the first clinical guidelines for cancer immunotherapy treatment in special challenging populations. Cancer immunotherapy in chronically infected or immunosuppressed patients is feasible but needs a multidisciplinary approach in order to decrease the risk of complications related to the coexistent comorbidities. BMJ Publishing Group 2021-03-28 /pmc/articles/PMC8009216/ /pubmed/33782108 http://dx.doi.org/10.1136/jitc-2020-001664 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Position Article and Guidelines Gonzalez-Cao, Maria Puertolas, Teresa Riveiro, Mar Muñoz-Couselo, Eva Ortiz, Carolina Paredes, Roger Podzamczer, Daniel Manzano, Jose Luis Molto, Jose Revollo, Boris Carrera, Cristina Mateu, Lourdes Fancelli, Sara Espinosa, Enrique Clotet, Bonaventura Martinez-Picado, Javier Cerezuela, Pablo Soria, Ainara Marquez-Rodas, Ivan Mandala, Mario Berrocal, Alfonso Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM) |
title | Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM) |
title_full | Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM) |
title_fullStr | Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM) |
title_full_unstemmed | Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM) |
title_short | Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM) |
title_sort | cancer immunotherapy in special challenging populations: recommendations of the advisory committee of spanish melanoma group (gem) |
topic | Position Article and Guidelines |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009216/ https://www.ncbi.nlm.nih.gov/pubmed/33782108 http://dx.doi.org/10.1136/jitc-2020-001664 |
work_keys_str_mv | AT gonzalezcaomaria cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem AT puertolasteresa cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem AT riveiromar cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem AT munozcouseloeva cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem AT ortizcarolina cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem AT paredesroger cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem AT podzamczerdaniel cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem AT manzanojoseluis cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem AT moltojose cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem AT revolloboris cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem AT carreracristina cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem AT mateulourdes cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem AT fancellisara cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem AT espinosaenrique cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem AT clotetbonaventura cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem AT martinezpicadojavier cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem AT cerezuelapablo cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem AT soriaainara cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem AT marquezrodasivan cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem AT mandalamario cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem AT berrocalalfonso cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem AT cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem |